No Data
No Data
Express News | Bicycle Therapeutics PLC: Dose Selection and Topline Data From Phase 2/3 Duravelo-2 Trial Planned for 2H 2025
Express News | Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging Nectin4 Gene Amplification
Bicycle Therapeutics Expands Clinical Advisory Board With Three Distinguished Global Oncology Experts
European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading
Needham Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $38
Positive Outlook on Bicycle Therapeutics Driven by Promising Data and Upcoming Updates